Natus Medical surged nearly 30% in morning trading after being taken private by ArchiMed for $1.2 billion.
"The sale of Natus to ArchiMed will provide our shareholders with immediate and substantial cash value, as well as a compelling premium, and the Board has unanimously agreed that this transaction is in the best interests of our shareholders," said Joshua Levine, chairman of Natus.
The transaction is expected to close in the third quarter and has fully committed equity financing from funds affiliated with ArchiMed, the companies said. Natus may still solicit proposals from third parties for a period of 30 days.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments